60 Degrees Pharmaceuticals, Inc.
SXTPNASDAQ
Healthcare
$1.86
-0.01(-0.27%)
Mkt Cap $2M
$1.42
$13.80
52-Week Range
At a Glance
AI-generated60 Degrees Pharmaceuticals achieved revenue growth in FY2025, but continued operating losses and cash burn highlight ongoing challenges in achieving sustainable profitability despite improved sales dynamics.
8-K
On February 11, 2026, 60 Degrees Pharmaceuticals, Inc. received notification from Nasdaq that it had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Consequently, the previously scheduled hearing was cancelled, and the Company's common stock will continue to be listed on The Nasdaq Capital Market.$2M
Market Cap
$845.8K
Revenue
-$7M
Net Income
Employees3
Fundamentals
How The Business Makes Money
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001946563
ISINUS83006G5009
CUSIP83006G401
Phone202 327 5422
Address1025 Connecticut Avenue NW, Washington, DC, 20036, US
SEC EDGAR